• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ProKidney Corp. (Amendment)

    11/3/23 9:00:16 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PROK alert in real time by email
    SC 13D/A 1 tm2329254d2_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

     

    ProKidney Corp.

    (Name of Issuer)

     

    Class A ordinary shares, par value $0.0001 per share
    (Title of Class of Securities)

     

    G7S53R104
    (CUSIP Number)

     

    Chamath Palihapitiya
    c/o SC Master Holdings, LLC
    506 Santa Cruz Avenue, Suite 300
    Menlo Park, California 94025
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 3, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     CUSIP No. G7S53R104

     

    1 NAMES OF REPORTING PERSONS
    Chamath Palihapitiya
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) 
    ¨ (b) ¨
    3

    SEC USE ONLY

     

    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
    WC
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
    ¨
    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0
    8 SHARED VOTING POWER
    11,795,700(1)
    9 SOLE DISPOSITIVE POWER
    0
    10 SHARED DISPOSITIVE POWER
    11,795,700(1)

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    11,795,700(1)
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    17.6%
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

     

    (1)Consisting of 11,795,700 Class A ordinary shares, par value $0.0001 per share, of ProKidney Corp. (the “Issuer,” and its Class A ordinary shares, the “Issuer Class A ordinary shares”). SC PIPE Holdings LLC (“SC PIPE Holdings”) is the record holder of 6,722,700 of the Issuer Class A ordinary shares reported herein. SC PIPE Holdings is controlled by Mr. Palihapitiya. Mr. Palihapitiya may be deemed to beneficially own Issuer Class A ordinary shares held directly by SC PIPE Holdings by virtue of his indirect interests in SC PIPE Holdings or his control over SC PIPE Holdings, as the case may be. SC Master Holdings, LLC (“SC Master Holdings”) is the record holder of 2,073,000 of the Issuer Class A ordinary shares reported herein. SC Master Holdings is controlled by Mr. Palihapitiya. Mr. Palihapitiya may be deemed to beneficially own Issuer Class A ordinary shares held directly by SC Master Holdings by virtue of his indirect interests in SC Master Holdings or his control over SC Master Holdings, as the case may be. A trust for the benefit of members of Mr. Palihapitiya’s immediate family (the “Trust”) is the record holder of 3,000,000 of the Issuer Class A ordinary shares reported herein. Mr. Palihapitiya may be deemed to beneficially own Issuer Class A ordinary shares held directly by the Trust.

     

    -1-

     

     

    1 NAMES OF REPORTING PERSONS
    SC PIPE Holdings LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) 
    ¨ (b) ¨
    3

    SEC USE ONLY

     

    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
    WC
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
    ¨
    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0
    8 SHARED VOTING POWER
    6,722,700(1)
    9 SOLE DISPOSITIVE POWER
    0
    10 SHARED DISPOSITIVE POWER
    6,722,700(1)

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    6,722,700(1)
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    10.0%
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

     

    (1)Consisting of 6,722,700 Issuer Class A ordinary shares held of record by SC PIPE Holdings. SC PIPE Holdings is controlled by Mr. Palihapitiya and SC Master Holdings is the sole member of SC PIPE Holdings. Mr. Palihapitiya and SC Master Holdings may be deemed to beneficially own Issuer Class A ordinary shares held directly by SC PIPE Holdings by virtue of their indirect or direct interests in SC PIPE Holdings or their control over SC PIPE Holdings, as the case may be.

     

    -2-

     

     

    1 NAMES OF REPORTING PERSONS
    SC Master Holdings, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) 
    ¨ (b) ¨
    3

    SEC USE ONLY

     

    4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
    WC
    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
    ¨
    6 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    7 SOLE VOTING POWER
    0
    8 SHARED VOTING POWER
    8,795,700(1)
    9 SOLE DISPOSITIVE POWER
    0
    10 SHARED DISPOSITIVE POWER
    8,795,700(1)

     

    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,795,700(1)
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    13.1%
    14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

      

     

    (1)Consisting of 8,795,700 Issuer Class A ordinary shares. SC PIPE Holdings is the record holder of 6,722,700 of the Issuer Class A ordinary shares reported herein. SC Master Holdings is the sole member of SC PIPE Holdings. SC Master Holdings may be deemed to beneficially own Issuer Class A ordinary shares held directly by SC PIPE Holdings by virtue of its direct interests in SC PIPE Holdings or its control over SC PIPE Holdings, as the case may be. SC Master Holdings is the record holder of 2,073,000 of the Issuer Class A ordinary shares reported herein. SC Master Holdings is controlled by Mr. Palihapitiya. Mr. Palihapitiya may be deemed to beneficially own Issuer Class A ordinary shares held directly by SC Master Holdings by virtue of his indirect interests in SC Master Holdings or his control over SC Master Holdings, as the case may be.

     

    -3-

     

     

    Item 1. Security and Issuer.

     

    This Amendment No. 4 to Schedule 13D (this “Amendment”) amends and supplements the Schedule 13D filed with the United States Securities and Exchange Commission on July 20, 2022, as amended to date (the “Schedule 13D”), relating to the Class A ordinary shares, par value $0.0001 per share (the “Issuer Class A ordinary shares”), of ProKidney Corp., a Cayman Islands exempted company limited by shares (the “Issuer”). The address of the principal executive office of the Issuer is 2000 Frontis Plaza Blvd., Ste 250, Winston-Salem, NC 27103.

     

    Each item below amends and supplements the information disclosed under the corresponding item of the Schedule 13D. Capitalized terms defined in the Schedule 13D are used herein as so defined.

     

    Item 2. Identity and Background.

     

    Item 2 of the Schedule 13D is hereby amended and supplemented by the following:

     

    The information contained on the cover pages of this Amendment is incorporated herein by reference.

     

    Item 5. Interest in Securities of the Issuer.

     

    Items 5(a)-(b) of the Schedule 13D are hereby amended and supplemented by the following:

     

    The information contained on the cover pages of this Amendment is incorporated herein by reference. The aggregate percentage of Issuer Class A ordinary shares reported as beneficially owned by each Reporting Person is determined in accordance with SEC rules and is based upon 67,016,286 Issuer Class A ordinary shares outstanding, which is the total number of Issuer Class A ordinary shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2023, as adjusted for the conversion by unaffiliated persons of an aggregate of 5,426,055 common units of the Issuer and an equal number of Class B ordinary shares of the Issuer into Issuer Class A ordinary shares as reported on such persons’ Form 4s, filed with the SEC on August 29, 2023 and November 1, 2023.

     

    Item 5(c) of the Schedule 13D is hereby amended and supplemented by adding the following:

     

    On October 27, 2023, SC PIPE Holdings LLC sold 92,500 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.5857 per share.

     

    On October 30, 2023, SC PIPE Holdings LLC sold 157,000 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.6531 per share.

     

    On October 31, 2023, SC PIPE Holdings LLC sold 141,900 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.6864 per share.

     

    On November 1, 2023, SC PIPE Holdings LLC sold 123,400 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.6181 per share.

     

    On November 2, 2023, SC PIPE Holdings LLC sold 133,700 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.7349 per share.

     

    On November 3, 2023, SC PIPE Holdings LLC sold 148,300 Issuer Class A ordinary shares in open market transactions, at a weighted average price of $1.7294 per share.

     

    -4-

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 3, 2023

     

      CHAMATH PALIHAPITIYA
       
      By: /s/ Chamath Palihapitiya
       
       
      SC PIPE HOLDINGS LLC
       
      By: SC MASTER HOLDINGS, LLC, its sole member
       
      By: SOCIAL CAPITAL GROUP LLC, its sole member
         
         
      By: /s/ Chamath Palihapitiya
        Name: Chamath Palihapitiya
        Title: Chief Executive Officer
           
      SC MASTER HOLDINGS, LLC
       
      By: SOCIAL CAPITAL GROUP LLC, its sole member
         
         
      By: /s/ Chamath Palihapitiya
        Name: Chamath Palihapitiya
        Title: Chief Executive Officer

     

    -5-

     

    Get the next $PROK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROK

    DatePrice TargetRatingAnalyst
    9/30/2024Neutral
    JP Morgan
    9/10/2024$6.00Buy
    Guggenheim
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    1/2/2024Buy → Neutral
    BofA Securities
    7/25/2023$16.00Buy
    BTIG Research
    12/21/2022$15.00Buy
    Jefferies
    11/10/2022$13.00Equal-Weight
    Morgan Stanley
    10/18/2022$18.00Buy
    UBS
    More analyst ratings

    $PROK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan initiated coverage on ProKidney Corp.

      JP Morgan initiated coverage of ProKidney Corp. with a rating of Neutral

      9/30/24 7:50:41 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on ProKidney Corp. with a new price target

      Guggenheim initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $6.00

      9/10/24 7:56:11 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on ProKidney Corp. with a new price target

      Morgan Stanley resumed coverage of ProKidney Corp. with a rating of Equal-Weight and set a new price target of $3.00

      3/7/24 7:33:04 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      11/8/24 10:13:46 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      10/22/24 3:32:15 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ProKidney Corp.

      SC 13D/A - PROKIDNEY CORP. (0001850270) (Subject)

      6/25/24 4:08:10 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProKidney Reports Full Year 2024 Financial Results and Business Highlights

      Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-2025Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025; interim data from June 2024 showed kidney function stabilization for 18 months in patients with advanced CKD and diabetesEnd

      3/17/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare ConferenceDate:January 15, 2025Time:7:30am PSTFormat:PresentationWebcast:Link   The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website

      1/7/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

      WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: Evercore HealthCONx ConferenceDate:December 3, 2024Time:8:45am ETFormat:Fireside ChatWebcast:Link  Citi Global Healthcare ConferenceDate:December 4, 2024Format:One-on-one meetings   The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab w

      11/26/24 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Leadership Updates

    Live Leadership Updates

    See more
    • ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

      Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall

      9/3/24 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Business Updates and First Quarter 2024 Financial Results

      Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su

      5/10/24 7:00:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

      WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch

      3/21/24 7:49:56 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ProKidney Corp.

      SCHEDULE 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      5/6/25 3:45:08 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by ProKidney Corp.

      EFFECT - PROKIDNEY CORP. (0001850270) (Filer)

      4/29/25 12:15:06 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by ProKidney Corp.

      424B3 - PROKIDNEY CORP. (0001850270) (Filer)

      4/28/25 4:51:14 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Financials

    Live finance-specific insights

    See more
    • ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

      Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical

      6/10/24 6:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Third Quarter Financial Results

      WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the

      11/14/23 6:05:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

      Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu

      11/13/23 5:02:13 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care